ALX Oncology (ALXO) CFO receives 303,000 stock options at $1.48 exercise price

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. reported that its Chief Financial Officer, Shantharam Harish, received a grant of stock options on January 26, 2026. The award covers 303,000 stock options with an exercise price of $1.48 per share, giving the right to buy common stock.

The options vest in 48 equal monthly installments starting on February 26, 2026, and are scheduled to expire on January 25, 2036. Following this grant, Harish beneficially owns 303,000 derivative securities directly in the form of these stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shantharam Harish

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	303,000	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 303,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/28/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shantharam Harish

(Last)

(First)

(Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$1.48	01/26/2026		A		303,000		⁽¹⁾	01/25/2036	Common Stock	303,000	$0	303,000	D

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

	/s/ Shelly Pinto, by power of attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ALX Oncology (ALXO) disclose for the CFO?

ALX Oncology disclosed that Chief Financial Officer Shantharam Harish received a grant of 303,000 stock options on January 26, 2026. These derivative securities are held directly and give him the right to purchase common stock at a fixed exercise price.

How many stock options were granted to the ALXO CFO and at what exercise price?

The ALXO CFO received 303,000 stock options with an exercise price of $1.48 per share. This grant provides the right to buy ALX Oncology common stock at that price, subject to the vesting schedule and the stated expiration date.

What is the vesting schedule for the ALX Oncology CFO’s new stock options?

The options vest in 48 equal monthly installments beginning on February 26, 2026. This means a portion of the 303,000 options becomes exercisable each month over four years, aligning continued service with the gradual availability of the shares.

When do the newly granted ALXO stock options to the CFO expire?

The stock options granted to the ALXO CFO on January 26, 2026, are scheduled to expire on January 25, 2036. After that expiration date, any unexercised options will no longer be usable to purchase ALX Oncology common stock.

Is the ALXO CFO’s stock option grant reported as direct or indirect ownership?

The filing reports the CFO’s 303,000 stock options as directly owned. There is no indication in the footnotes that another entity holds voting or investment authority, so the derivative securities are attributed to him personally as direct beneficial ownership.

What type of security was involved in the ALX Oncology Form 4 filing?

The filing involves a derivative security classified as a stock option, described as a right to buy common stock. It carries a $1.48 exercise price and covers 303,000 underlying common shares, subject to the specified vesting and expiration terms.